An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir

BACKGROUND: The World Health Organisation approved boosted atazanavir as a preferred second line protease inhibitor in 2010. This is as an alternative to the current boosted lopinavir. Atazanavir has a lower genetic barrier than lopinavir. We compared the virological outcomes of patients during the...

Descripción completa

Detalles Bibliográficos
Autores principales: Laker, Eva Agnes Odongpiny, Nabaggala, Maria Sarah, Kaimal, Arvind, Nalwanga, Damalie, Castelnuovo, Barbara, Musubire, Abdu, Kiragga, Agnes, Lamorde, Mohammed, Ratanshi, Rosalind Parkes-
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434787/
https://www.ncbi.nlm.nih.gov/pubmed/30909871
http://dx.doi.org/10.1186/s12879-019-3907-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434787/
https://www.ncbi.nlm.nih.gov/pubmed/30909871
http://dx.doi.org/10.1186/s12879-019-3907-5

Ejemplares similares